Next Article in Journal
Proteomic Profiling of Pre- and Post-Surgery Saliva of Glioblastoma Patients: A Pilot Investigation
Next Article in Special Issue
AdipoRon’s Impact on Alzheimer’s Disease—A Systematic Review and Meta-Analysis
Previous Article in Journal
Evaluation of In Vitro Biological Activity of Flavanone/Chromanone Derivatives: Molecular Analysis of Anticancer Mechanisms in Colorectal Cancer
Previous Article in Special Issue
IL-1 Blockade Mitigates Autism and Cerebral Palsy Traits in Offspring In-Utero Exposed to Group B Streptococcus Chorioamnionitis
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 25
Issue 23
10.3390/ijms252312981
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Brief Report

RNA Editing Signatures Powered by Artificial Intelligence: A New Frontier in Differentiating Schizophrenia, Bipolar, and Schizoaffective Disorders

by
Francisco J. Checa-Robles
1,2,
Nicolas Salvetat
1,2,
Christopher Cayzac
1,2,
Mary Menhem
1,2,
Mathieu Favier
1,2,
Diana Vetter
1,2,
Ilhème Ouna
2,
João V. Nani
3,4,
Mirian A. F. Hayashi
3,4,
Elisa Brietzke
5 and
Dinah Weissmann
1,2,*
1
ALCEDIAG, Parc Euromédecine, 34184 Montpellier Cedex 4, France
2
Sys2Diag, UMR 9005 CNRS/ALCEN, Parc Euromédecine, 34184 Montpellier Cedex 4, France
3
Department of Pharmacology, Escola Paulista de Medicina (EPM), Universidade Federal de São Paulo (UNIFESP), São Paulo CEP 04044-20, Brazil
4
National Institute for Translational Medicine (INCT-TM, CNPq/FAPESP/CAPES), Ribeirão Preto CEP 14040-900, Brazil
5
Department of Psychiatry, School of Medicine, Queen’s University, Kingston, ON K7L 7X3, Canada
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2024, 25(23), 12981; https://doi.org/10.3390/ijms252312981
Submission received: 22 October 2024 / Revised: 22 November 2024 / Accepted: 29 November 2024 / Published: 3 December 2024
(This article belongs to the Special Issue Translating Molecular Psychiatry: From Biomarkers to Personalized Therapies)
Browse Figures
Versions Notes

Abstract

Mental health disorders are devastating illnesses, often misdiagnosed due to overlapping clinical symptoms. Among these conditions, bipolar disorder, schizophrenia, and schizoaffective disorder are particularly difficult to distinguish, as they share alternating positive and negative mood symptoms. Accurate and timely diagnosis of these diseases is crucial to ensure effective treatment and to tailor therapeutic management to each individual patient. In this context, it is essential to move beyond standard clinical assessment and employ innovative approaches to identify new biomarkers that can be reliably quantified. We previously identified a panel of RNA editing biomarkers capable of differentiating healthy controls from depressed patients and, among depressed patients, those with major depressive disorder and those with bipolar disorder. In this study, we integrated Adenosine-to-Inosine RNA editing blood biomarkers with clinical data through machine learning algorithms to establish specific signatures for bipolar disorder and schizophrenia spectrum disorders. This groundbreaking study paves the way for the application of RNA editing in other psychiatric disorders, such as schizophrenia and schizoaffective disorder. It represents a first proof-of-concept and provides compelling evidence for the establishment of an RNA editing signature for the diagnosis of these psychiatric conditions.
Keywords: schizophrenia; RNA editing; artificial intelligence schizophrenia; RNA editing; artificial intelligence

Share and Cite

MDPI and ACS Style

Checa-Robles, F.J.; Salvetat, N.; Cayzac, C.; Menhem, M.; Favier, M.; Vetter, D.; Ouna, I.; Nani, J.V.; Hayashi, M.A.F.; Brietzke, E.; et al. RNA Editing Signatures Powered by Artificial Intelligence: A New Frontier in Differentiating Schizophrenia, Bipolar, and Schizoaffective Disorders. Int. J. Mol. Sci. 2024, 25, 12981. https://doi.org/10.3390/ijms252312981

AMA Style

Checa-Robles FJ, Salvetat N, Cayzac C, Menhem M, Favier M, Vetter D, Ouna I, Nani JV, Hayashi MAF, Brietzke E, et al. RNA Editing Signatures Powered by Artificial Intelligence: A New Frontier in Differentiating Schizophrenia, Bipolar, and Schizoaffective Disorders. International Journal of Molecular Sciences. 2024; 25(23):12981. https://doi.org/10.3390/ijms252312981

Chicago/Turabian Style

Checa-Robles, Francisco J., Nicolas Salvetat, Christopher Cayzac, Mary Menhem, Mathieu Favier, Diana Vetter, Ilhème Ouna, João V. Nani, Mirian A. F. Hayashi, Elisa Brietzke, and et al. 2024. "RNA Editing Signatures Powered by Artificial Intelligence: A New Frontier in Differentiating Schizophrenia, Bipolar, and Schizoaffective Disorders" International Journal of Molecular Sciences 25, no. 23: 12981. https://doi.org/10.3390/ijms252312981

APA Style

Checa-Robles, F. J., Salvetat, N., Cayzac, C., Menhem, M., Favier, M., Vetter, D., Ouna, I., Nani, J. V., Hayashi, M. A. F., Brietzke, E., & Weissmann, D. (2024). RNA Editing Signatures Powered by Artificial Intelligence: A New Frontier in Differentiating Schizophrenia, Bipolar, and Schizoaffective Disorders. International Journal of Molecular Sciences, 25(23), 12981. https://doi.org/10.3390/ijms252312981

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop